Brokerages Expect Innophos Holdings, Inc. (IPHS) to Announce $0.56 EPS

Innophos Holdings, Inc. (NASDAQ:IPHS) has been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.

Zacks has also assigned Innophos an industry rank of 78 out of 265 based on the ratings given to its competitors.

A number of brokerages have issued reports on IPHS. BidaskClub lowered shares of Innophos from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research lowered shares of Innophos from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Innophos in a report on Wednesday, November 1st.

A number of institutional investors and hedge funds have recently made changes to their positions in IPHS. Old Mutual Global Investors UK Ltd. purchased a new stake in Innophos during the 3rd quarter valued at approximately $109,000. Public Employees Retirement System of Ohio grew its holdings in Innophos by 5.9% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 2,824 shares of the specialty chemicals company’s stock valued at $124,000 after buying an additional 157 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of Innophos in the third quarter valued at $193,000. Piedmont Investment Advisors LLC purchased a new position in shares of Innophos in the third quarter valued at $209,000. Finally, Pacad Investment Ltd. grew its holdings in shares of Innophos by 19.5% in the second quarter. Pacad Investment Ltd. now owns 4,900 shares of the specialty chemicals company’s stock valued at $215,000 after purchasing an additional 800 shares in the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.

Innophos (NASDAQ:IPHS) traded down $0.52 during trading on Monday, reaching $44.97. 167,079 shares of the company traded hands, compared to its average volume of 116,462. The stock has a market cap of $902.63, a price-to-earnings ratio of 18.79 and a beta of 0.86. Innophos has a one year low of $41.66 and a one year high of $58.22. The company has a quick ratio of 1.49, a current ratio of 2.86 and a debt-to-equity ratio of 0.83.

Innophos (NASDAQ:IPHS) last released its earnings results on Tuesday, October 31st. The specialty chemicals company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.06. The company had revenue of $184.00 million during the quarter, compared to analyst estimates of $179.33 million. Innophos had a net margin of 6.19% and a return on equity of 13.90%. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.69 EPS. analysts predict that Innophos will post 2.5 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 6th. Shareholders of record on Friday, November 17th were issued a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 4.27%. The ex-dividend date of this dividend was Thursday, November 16th. Innophos’s dividend payout ratio (DPR) is currently 88.48%.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/brokerages-expect-innophos-holdings-inc-iphs-to-announce-0-56-eps.html.

About Innophos

Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply